VistaGen Kick Starts Late-Stage Social Anxiety Disorder Study with PH94B

by Vandana Singh, Benzinga Editor

May 26, 2021 9:28 AM | 22 seconds read

VistaGen Therapeutics Inc VTGN has initiated its PALISADE Phase 3 study to evaluate PH94B for the acute treatment of Social Anxiety Disorder (SAD).
PH94B is an odorless, rapid-onset, investigational pherine nasal spray.
PALISADE-1 is being conducted with approximately 200 subjects.
Topline results from PALISADE-1 are anticipated in mid-2022.
Price Action: VTGN shares are up 1.35% at $3.01 during the premarket session on the last check Wednesday.

Posted In: News Penny Stocks Health Care Small Cap FDA General anxiety Briefs Phase 3 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.